Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2014—OraSure Technologies has reached an agreement with Thermo Fisher Scientific to develop and supply up to 12 homogenous, fully automated oral fluid drugs-of-abuse assays to be used with OraSure’s new Intercept oral fluid specimen collection device. OraSure will have the right to purchase and resell the assays in the U.S. and certain foreign countries, subject to receipt of applicable regulatory approvals.
February 2014—EKF Molecular Diagnostics launched four PointMan DNA enrichment kits for the research-use-only market, with planned diagnostic registration in Europe in 2014. As a real-time PCR technology, PointMan provides reliable and extremely sensitive detection of cancer mutations by amplifying the target sequence of interest in a background of wild-type genes. Using this technology, the enrichment kits are an ideal research tool for understanding biomarker and drug response.
February 2014—Ventana Medical Systems’ HER2/neu (4B5) Rabbit Monoclonal Primary Antibody assay is a companion diagnostic for detecting HER2 protein expression in patients who, in countries where the drugs are approved, may be appropriate candidates for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine).
February 2014—To meet the needs of today’s next-generation sequencing projects, Aurora Biomed offers the VERSA NGS Library Prep Workstation for high throughput preparation of sample libraries. VERSA enables automated processing of up to 96 libraries in parallel with the high precision needed for quality results.
February 2014—Swift Biosciences announced the launch of the Accel-NGS PCR-free DNA Library Kit for Illumina next-generation sequencing systems. The kit is designed to bring low input requirement, PCR-free capability, and fast, easy workflow to the Illumina platform.
February 2014—Hamilton Scientific recently completed installation of 60 fume hoods and 120 laboratory benches in the 200,000-sq.-ft. lab space at the Wisconsin Energy Institute and Consolidated Forensic Lab. The laboratory workstation design was developed in response to the customer’s request for ease of utility access while simultaneously allowing for movable laboratory benches.
February 2014—TissueMark, developed by Belfast-based digital pathology specialists PathXL, was launched at the 2013 annual meeting of the Association for Molecular Pathology. It analyzes the structural patterns in tissue samples and marks the boundaries of potentially cancerous sections for more detailed analysis.
February 2014—Empirical Bioscience, a company that produces high-grade PCR reagents and enzymes, has introduced rEVAlution qPCR Master Mix, an environmentally safe, ready-to-use hot start qPCR mixture specifically formulated with high-quality components to offer superior safety, speed, and signaling capabilities.
February 2014—Qiagen announced an agreement with Eli Lilly to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound. This is the third co-development project by Qiagen and Lilly to create companion diagnostics.
February 2014—Integrated DNA Technologies launched the latest addition to its portfolio of next-generation sequencing products, xGen Universal Blocking Oligos. By incorporating these oligos into target-capture experiments, users can decrease the complexity and increase the throughput of their target-capture experiment without degrading performance.
